PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.

PepGen Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alumis Inc. (ALMS) and PepGen Inc. (PEPG) with bulli...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Praxis Precision Medicines (PRAX), PepGen Inc. (PE...

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), PepGen Inc. (PEPG) and Omeros (OMER)

PepGen Inc. ( ($PEPG) ) has provided an announcement. On March 30, 2026, PepGen reported topline data from the lowest 5 mg/kg multiple ascending do...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PEPG	$1.67	0.00%	1.52M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PEPG	$1.67	0%	1.52M
3
4
5
6

PEPG

PEPG

Latest News for PEPG

Get PepGen Inc. Data in Excel

Get PepGen Inc. Data in Excel